Percutaneous coronary intervention (PCI) is considered the treatment of choice in ST-segment elevation myocardial infarction (STEMI). However, it is widely acknowledged that, in many cases, there are significant lesions in other coronary arteries. Previous randomized studies have shown that complete revascularization in a second procedure is more beneficial than intervention only in the culprit artery.<a href="https://solaci.org/en/2023/09/19/ami-and-multivessel-disease-can-we-perform-a-single-procedure/" title="Read more" >...</a>
What to Do in Cases of AMI with Multivessel Disease
The presence of lesions in multiple vessels is common in ST-segment elevation myocardial infarction (STEMI). It has been shown that, when they are treated in a second procedure, patients have a better outcome. To date, there is limited information available on percutaneous transluminal coronary angioplasty (PTCA) in vessels with severe non-culprit lesions during primary angioplasty.<a href="https://solaci.org/en/2023/09/12/what-to-do-in-cases-of-ami-with-multivessel-disease/" title="Read more" >...</a>
ACC 2023 | Complete Revascularization Strategies in patients with ACS and Multivessel Disease
In patients with acute coronary syndrome (ACS) and multivessel disease, complete revascularization is associated with better clinical outcomes. However, for non-culprit vessel revascularization the strategy remains unclear. The aim of this multicenter, open label, randomized, non-inferiority study, was to determine whether complete revascularization during index procedure is non inferior vs. staged. Primary end point was<a href="https://solaci.org/en/2023/03/08/acc-2023-complete-revascularization-strategies-in-patients-with-acs-and-multivessel-disease/" title="Read more" >...</a>
Should We Use Drug Coated Balloons in Patients with Multivessel Disease?
Recent studies have shown that a drug coated balloons (DCB) based approach resulted non inferior when compared against drug eluting stents (DES) only approach in patients with instent restenosis and de novo lesions in small vessel disease. So far, two international consensuses have reported the use of DCB is feasible and safe to treat native<a href="https://solaci.org/en/2023/02/22/should-we-use-drug-coated-balloons-in-patients-with-multivessel-disease/" title="Read more" >...</a>
SOLACI-SOCIME 2022 | Primary PCI in Multivessel Disease: A Case, Ten Lessons
Read the most outstanding articles from the first day of the SOLACI-SOCIME 2022 Congress. In this case, consult the presentation by Dr. Mauricio Cohen, entitled “Primary PCI in Multivessel Disease: A Case, Ten Lessons”
In Multivessel Disease, When Should Renal Impairment Be Considered?
Cardiovascular disease is one of the main causes of morbidity and mortality in patients with advanced chronic kidney disease (CKD), and vice-versa. Both diseases share risk factors, including, but not limited to, diabetes, high blood pressure, smoking, dyslipidemia, and old age. As kidney disease develops, its severity grade has been linked to more thrombotic events<a href="https://solaci.org/en/2022/04/27/in-multivessel-disease-when-should-renal-impairment-be-considered/" title="Read more" >...</a>
April 7th | Medtronic-SOLACI Masterclass with Gregg Stone: Revascularization in Patients with Multivessel Lesions
Join us in the third Medtronic-SOLACI masterclass with Dr. Gregg Stone (USA) and renowned Latin-American panelists. In this last session of this cycle of 3 masterclasses organized alongside Medtronic, Dr. Stone will discuss revascularization in patients with multivessel lesions. Date: April 7th, 2022, at 07:30 p.m. (Argentina/Brazil time, UTC -3). As usual, this event is<a href="https://solaci.org/en/2022/04/05/april-7th-medtronic-solaci-masterclass-with-gregg-stone-revascularization-in-patients-with-multivessel-lesions/" title="Read more" >...</a>
[APT Medical Sponsored Clinical Case] Bilateral Distal Transradial Access for Chronic Total Occlusion Recanalization and Multivessel Coronary Disease Percutaneous Intervention
Introduction Chronic total occlusion (CTO) represents the most challenging setting for percutaneous coronary intervention (PCI) and multivessel coronary disease (MCD) is often treated in a staggered manner and in a deferred procedure. Although transfemoral is one of the common access site, the transradial access (TRA) has been used with similar procedural success [1]. The distal<a href="https://solaci.org/en/2021/04/28/apt-medical-sponsored-clinical-case-bilateral-distal-transradial-access-for-chronic-total-occlusion-recanalization-and-multivessel-coronary-disease-percutaneous-intervention/" title="Read more" >...</a>
Is Complete Revascularization the Right Choice in Acute Myocardial Infarction with Multivessel Disease?
Courtesy of Dr. Carlos Fava. Primary coronary angioplasty has been the treatment of choice for acute myocardial infarction (MI) for many years, but such strategy is associated with nonculprit lesions in a large group of patients. While it has been proven that nonculprit-lesion revascularization offers better outcomes, the groups that would benefit from it are<a href="https://solaci.org/en/2019/09/13/is-complete-revascularization-the-right-choice-in-acute-myocardial-infarction-with-multivessel-disease/" title="Read more" >...</a>
ESC 2019 | COMPLETE: Definitive Evidence for Infarction with Multivessel Disease
For patients with ST-segment elevation acute myocardial infarction and multivessel disease beyond the culprit artery, complete revascularization is superior to culprit-only treatment as regards the final endpoint, a composite of cardiovascular death, infarction, and ischemia-driven revascularization over a mean follow-up of 3 years. This information derives from long-awaited randomized study COMPLETE, finally presented at the<a href="https://solaci.org/en/2019/09/05/esc-2019-complete-definitive-evidence-for-infarction-with-multivessel-disease/" title="Read more" >...</a>